Skip to main content
Retour
Watch Compare

Vistagen Therapeutics, Inc.

Qualité des données : 83%
VTGN
Nasdaq Manufacturing Chemicals
0,56 €
▲ 0,01 € (1,60%)
Cap. Boursière: 22,15 M
Prix
0,56 €
Cap. Boursière
22,15 M
Fourchette du Jour
0,53 € — 0,57 €
Fourchette 52 Semaines
0,43 € — 5,14 €
Volume
154 131
Ouverture 0,55 €
Moyenne 50J / 200J
0,59 €
4,44% below
Moyenne 50J / 200J
2,39 €
76,58% below

Quick Summary

Points Clés

Negative free cash flow of -60,30 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-114,36%
En dessous de la moyenne du secteur (-51,02%)
ROIC-92,96%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio4,67
Interest CoverageN/A

Valorisation

PE (TTM)
-0,33
Au-dessus de la moyenne du secteur (-1,98)
P/B Ratio0,43
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (44 pairs)
Métrique Action Médiane du Secteur
P/E -0,3 -2,0
P/B 0,4 5,1
ROE % -114,4 -51,0
Net Margin % — -150,2
Rev Growth 5Y % — 9,3
D/E — 0,3

ETFs Holding This Stock

PSIL logo PSIL AdvisorShares Psychedelics ETF
4,29% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -67,05 M
ROE -114,36% ROA -91,85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -60,30 M
ROIC -92,96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,67
Interest Coverage N/A Asset Turnover N/A
Working Capital 49,72 M Tangible Book Value 50,92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,33 Forward P/E N/A
P/B Ratio 0,43 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -272,25%
Market Cap 22,15 M Enterprise Value -25,22 M
Per Share
EPS (Diluted TTM) -1,90 Revenue / Share N/A
FCF / Share -1,52 OCF / Share -1,52
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 89,94%
SBC-Adj. FCF -64,49 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — -227 000,0 1,11 M 1,09 M
Net Income -51,42 M -29,36 M -59,25 M -47,76 M -17,93 M
EPS (Diluted) -1,67 -1,52 — — —
Gross Profit — — — — —
Operating Income -55,97 M -33,02 M -59,27 M -47,78 M -17,93 M
EBITDA — — — — —
R&D Expenses 39,38 M 20,02 M 44,38 M 35,41 M 12,48 M
SG&A Expenses — — — — —
D&A 150 000,0 127 000,0 129 500,0 153 500,0 117 600,0
Interest Expense — — 26 200,0 19 900,0 1 600,0
Income Tax 7 000,0 4 000,0 5 900,0 3 400,0 2 600,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 84,34 M 123,65 M 21,09 M 74,64 M 108,28 M
Total Liabilities 13,95 M 9,37 M 9,01 M 9,93 M 16,30 M
Shareholders' Equity 70,39 M 114,29 M 12,08 M 64,72 M 91,98 M
Total Debt — — — — —
Cash & Equivalents 67,13 M 119,17 M 16,64 M 68,14 M 103,11 M
Current Assets 82,08 M 120,67 M 17,51 M 71,00 M 104,12 M
Current Liabilities 12,61 M 5,12 M 4,57 M 5,77 M 4,19 M